MAM01, a human monoclonal antibody targeting the conserved NANP repeat region of P. falciparum circumsporozoite protein, demonstrated safety and clinical proof-of-concept for malaria prevention in malaria-naive adults.
Phase 1 adaptive dose-escalation trial showed no treatment-related serious adverse events and identified a protective serum concentration threshold (>88 µg/mL).
MAM01 efficacy aligns with emerging evidence from related monoclonal antibodies such as CIS43LS and L9LS that offer potential for simplified malaria prophylaxis.
Future feasibility depends on optimizing dose regimens, lowering manufacturing costs, and targeting populations at highest risk.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.